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Abstract
Introduction MUC1 is an oncoprotein whose overexpression
correlates with aggressiveness of tumors and poor survival of
cancer patients. Many of the oncogenic effects of MUC1 are
believed to occur through interaction of its cytoplasmic tail with
signaling molecules. As expected for a protein with oncogenic
functions, MUC1 is linked to regulation of proliferation,
apoptosis, invasion, and transcription.
Methods To clarify the role of MUC1 in cancer, we transfected
two breast cancer cell lines (MDA-MB-468 and BT-20) with
small interfering (si)RNA directed against MUC1 and analyzed
transcriptional responses and oncogenic events (proliferation,
apoptosis and invasion).
Results Transcription of several genes was altered after
transfection of MUC1 siRNA, including decreased MAP2K1
(MEK1), JUN, PDGFA, CDC25A, VEGF and ITGAV (integrin
αv), and increased TNF, RAF1, and MMP2. Additional changes
were seen at the protein level, such as increased expression of
c-Myc, heightened phosphorylation of AKT, and decreased
activation of MEK1/2 and ERK1/2. These were correlated with
cellular events, as MUC1 siRNA in the MDA-MB-468 line
decreased proliferation and invasion, and increased stress-
induced apoptosis. Intriguingly, BT-20 cells displayed similar
levels of apoptosis regardless of siRNA, and actually increased
proliferation after MUC1 siRNA.
Conclusion These results further the growing knowledge of the
role of MUC1 in transcription, and suggest that the regulation of
MUC1 in breast cancer may be more complex than previously
appreciated. The differences between these two cell lines
emphasize the importance of understanding the context of cell-
specific signaling events when analyzing the oncogenic
functions of MUC1, and caution against generalizing the results
of individual cell lines without adequate confirmation in intact
biological systems.
Introduction
MUC1 is the founding member of the mucin family: proteins
characterized by heavy O-glycosylation centering around a
variable number of tandem repeats that are rich in serine and
threonine residues [1,2]. MUC1 is a transmembrane het-
erodimer with one subunit solely extracellular (MUC1-EX), and
the other subunit composed of a short extracellular stem, a sin-
gle transmembrane domain, and the cytoplasmic tail (together
called the MUC1-CT). MUC1 possesses both pro- and anti-
adhesive capacities, as the MUC1-EX provides binding sites
for a variety of adhesion proteins, while its large size and
extended structure prevents cell-cell contact [3-5].
Initially described as a tumor antigen overexpressed in >90%
of breast cancers, MUC1 is now known to be an oncogene
with roles in both tumor formation and progression [1,6].
Mouse studies have been integral to the current understand-
ing of MUC1 in cancer. Muc1 knockout mice (Muc1-/-; MUC1
is human; Muc1 is mouse) show a reduction in tumorigenic
phenotype when crossed onto mice overexpressing the Wnt-
1 [7] or polyomavirus middle T antigen [8] oncogenes in the
mammary gland. In contrast, MUC1 overexpression in the
mammary gland drives tumor formation [9], indicating that
MUC1 is a true oncogene.
Many of the oncogenic effects of MUC1 stem from its cyto-
plasmic tail, which binds to several proteins implicated in can-
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cer, including c-Src [10,11] and the epidermal growth factor
receptor (EGFR) family [12,13]. MUC1 stimulates mitogen
activated protein kinase (MAPK) signaling through the extra-
cellular signal regulated kinases (ERK1/2) [12,14]; this can
occur through MUC1 association with Grb2 and son of seven-
less to activate Ras [15]. ERK1/2 signaling is commonly stim-
ulated by the Ras-Raf-MEK (MAPK and ERK kinase) cascade
downstream of mitogens such as EGFR [16], and regulates
transcription via factors like the activator protein-1 complex.
Loss of MUC1 can reduce EGFR expression [17], providing
another means of affecting MAPK signaling. Our results
describe a novel mechanism by which MUC1 regulates the
ERK1/2 pathway, through modulating transcription of the
genes encoding MEK1, Raf-1, and c-Jun.
MUC1 expression correlates with increased survival in
response to cytotoxic or oxidative agents [18-21], and can
activate the phosphoinositol-3 kinase-AKT pathway as part of
an anti-apoptotic response [18]. MUC1 has also recently been
linked to transcription, as the MUC1-CT localizes to the
nucleus [22] and affects transcription by β-catenin [22,23],
FOXO3a [21], p53 [24], and estrogen receptor α [25]. How-
ever, there are indications that the role of MUC1 in oncogene-
sis is regulated by cell type and signaling context. For example,
MUC1 can stimulate Fas-mediated apoptosis [26], while
Muc1 is specifically down-regulated in c-neu-induced mam-
mary tumors [27]. This report emphasizes the complexity of
MUC1 signaling in breast cancer by contrasting results from
two established breast cancer cell lines.
To understand MUC1 function in cells with high endogenous
expression, that is, cells likely to have evolved with active
MUC1 signaling, we used small interfering RNA (siRNA) to
knock down MUC1 in MDA-MB-468 and BT-20 cells. We
then analyzed transcription of 84 genes involved in cancer, as
well as the effects upon cellular events linked to oncogenesis,
such as apoptosis and proliferation. Though the cell lines
show some similarity in transcriptional alterations after trans-
fection with MUC1 siRNA, their phenotypes are quite dissimi-
lar: MDA-MB-468 increases apoptosis and reduces
proliferation and invasion, while BT-20 proliferates more rap-
idly after loss of MUC1. This last may reflect the striking
amount of active AKT in BT-20; AKT activity is increased in
both cell lines after MUC1 siRNA, which agrees with a previ-
ous study of MUC1 siRNA [21], but disagrees with results
from 3Y1 fibroblasts [18]. Recent studies have emphasized
the complex and context-specific regulation of even such clas-
sic oncogenes as AKT [28]. The differences between the two
breast cancer cell lines in this study suggest that MUC1 onco-
genic functions are also subject to cell-specific regulation, and
stress the need for understanding the cellular signaling con-
text when interpreting results.
Materials and methods
Cell culture and siRNA transfection
MDA-MB-468 and BT-20 cells (American Type Culture Col-
lection) were cultured in Dulbecco's modified Eagle's medium
(Invitrogen, Carlsbad, CA, USA) plus 10% fetal calf serum, 1%
Glutamax (Invitrogen) and 1% penicillin/streptomycin. Stable
cell lines (468.Neo and 468.MUC1∆8) were selected with 0.5
mg/ml G418. For epidermal growth factor (EGF) stimulation,
MDA-MB-468 cells were serum-starved overnight and treated
for 10 minutes at 37°C with 100 ng/ml EGF. Transient siRNA
transfection was performed with Lipofectamine2000 (Invitro-
gen) and 100 nM siRNA oligonucleotides. The commercially
available siRNA constructs (all from Dharmacon, Lafayette,
CO, USA) were scrambled (siCONTROL non-targeting
siRNA #1), or directed against firefly luciferase (siCONTROL
non-targeting siRNA #2) or MUC1 (siGENOME smartpool).
The independent oligonucleotides designed in our laboratory
target sequences beginning at MUC1 codons 882 and 956,
and have been described previously [29]. The scrambled
siRNA construct was used only in BT-20 cells as it causes a
non-specific knockdown of MUC1 in the MDA-MB-468 line.
Cloning of MUC1 WT vector and stable transfection
Two silent mutations (G891A and T894C) were introduced
into the MUC1 cDNA (called MUC1∆8) to make it resistant to
the 882 siRNA that targets that region of the mRNA. The
mutant cDNA was cloned into the pLNCX.1 vector with neo-
mycin resistance (gift of Joseph Loftus, Mayo Clinic, Arizona,
USA). Stable transfection was performed with
Lipofectamine2000; cells were selected beginning 24 hours
post-transfection and maintained as a polyclonal population.
Western blots and antibodies
Cells were lysed in buffer (20 mM HEPES pH 8.0, 150 mM
sodium chloride, 1% Triton X-100, 2 mM EDTA) with commer-
cial protease (Complete inhibitor cocktail, Roche, Pleasanton,
CA, USA) and phosphatase inhibitors (10 mM sodium fluoride,
2 mM sodium vanadate, 50 µM ammonium molybdate). Pro-
tein concentration was determined by BCA (Pierce, Rockford,
IL, USA); 50 µg of lysate were loaded on SDS-PAGE gels for
each experiment, except for the pMEK1/2 blot in MDA-MB-
468, where 150 µg were used. Non-commercial antibodies
used were: BC2, a mouse monoclonal to the MUC1-EX (gift
of Dr McGuckin, Queensland University, Queensland, Aus-
tralia), and CT2, an Armenian hamster monoclonal to the
MUC1-CT developed in our lab [12]. Antibodies to pMEK1/2,
MEK1/2, ERK1/2, Myc, pAKT, AKT, β-tubulin (all Cell Signal-
ing, Danvers, MA, USA), β-actin and dpERK1/2 (both Sigma,
St. Louis, MO, USA) were used according to manufacturers'
recommendations. All antibodies except β-actin (1:2,500) and
dpERK1/2 (1:10,000) were used at 1:1,000 dilution for west-
ern blots. Flow cytometric analysis of MUC1 was done with
HMPV-FITC, which recognizes the core peptide of the MUC1-
EX tandem repeats (Pharmingen, San Diego, CA, USA). Bro-
modeoxyuridine (BrdU) staining was performed with a fluores-Available online http://breast-cancer-research.com/content/8/4/R37
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cently conjugated antibody to BrdU (BrdU-PE, BD
Biosciences, San Diego, CA, USA) as described below. Den-
sitometry was performed using the public domain ImageJ pro-
gram (developed at the NIH and available at [30]. Each band
was measured in three places; the results were averaged and
normalized to tubulin to control for loading.
Transwell invasion assays
Cells were serum-starved beginning 24 hours post-siRNA
transfection. Cells were re-plated in serum-free medium 48
hours post-transfection at 50,000 cells per insert (sized for
24-well plates), with serum-containing medium in the bottom
of the growth well as an attractant. Transwell inserts (BD Bio-
sciences) pre-coated with laminin, fibronectin, collagen IV, or
control (no matrix) were used, and cells were permitted to
invade for 48 hours. At this point (96 hours post-transfection),
visual inspection of the growth wells confirmed that negligible
numbers of cells went through to the bottom of the plate. Non-
invaded cells were swabbed from the tops of half of the inserts
('samples', containing only invaded cells), and retained in the
others ('controls', all cells). Inserts were stained for 10 minutes
with crystal violet (0.5% in 20% methanol) and washed with
water. Membranes were cut out and destained for 10 minutes
in 10% acetic acid in a 96-well plate; membranes were
removed and absorbance was read at 570 nm. Percent inva-
sion is defined as (absorbance of samples/absorbance of con-
trols) × 100.
[3H]Thymidine incorporation assays
Cells were re-plated in quadruplicate 24 hours post-siRNA
transfection at 15,000 cells/well (96-well plate) with [3H]thy-
midine (1 µCi/well), then incubated in normal conditions for 24
hours. At this time (48 hours post-siRNA transfection) excess
radioactivity was washed off and the cells were harvested and
read on a TopCount plate reader. Statistical analysis was per-
formed using JMP 5.1.2 software (SAS Institute, Inc., Cary,
NC, USA); the student's t test was used to determine p values
and significance was confirmed with Wilcoxon rank sum and
Pearson chi squared analyses.
BrdU incorporation
BrdU (50 µM) was given to cells 48 hours post-siRNA trans-
fection and permitted to incorporate for 1.5 hours. Cells were
then washed with PBS, trypsinized, and washed again. BrdU
staining was performed according to an adaptation of the
manufacturer's protocol: cells were re-suspended in PBS,
mixed 1:1 with -20°C neat ethanol, and incubated 1 hour at -
20°C to fix. Fixed cells were then washed gently and dena-
tured in 2 M HCl for 20 minutes at room temperature. Follow-
ing washing and 2 minute's incubation with 0.1 M Tris to
neutralize the acid, cells were re-suspended in FACS buffer
(0.5% fetal calf serum in PBS) and stained with Phycoerythrin
(PE)-conjugated anti-BrdU according to the manufacturer's
protocol for flow cytometry analysis on a FACScan instrument.
Apoptosis and trypan blue staining
Apoptosis was measured using a kit (BD Biosciences) con-
taining propidium iodide (PI) and FITC-conjugated annexin V.
Cells were stained according to the manufacturer's protocol
and the level of apoptosis determined by flow cytometry.
Quadrants are: early apoptosis (annexin V+/PI-, lower right)
late apoptosis (annexin V+/PI+, upper right) and non-apoptotic
cell death (annexin V-/PI+, upper left). Treatments for the stress
panel were: no treatment (control); DMSO as a control for
celecoxib; 20 mM celecoxib, brand name Celebrex™ (dis-
solved in DMSO) [31]; 0.2 mM H2O2 [32]; or 1 mg/mL G418
(Pfizer, New York, NY, USA).
Real-time PCR arrays
Transcriptional analysis using Cancer PathwayFinder RT2 pro-
filer arrays (SuperArray, Frederick, MD, USA) was performed
according to the manufacturer's protocol. Briefly, total RNA
was isolated using an RNeasy extraction kit (Qiagen, Valencia,
CA, USA); 1 µg of RNA was reverse transcribed with the
cDNA synthesis kit (SuperArray) and cDNA was subjected to
real-time PCR using SYBR green to detect product. Arrays
were performed independently at least twice for each cell line;
all PCR products were checked on agarose gels. Values were
obtained for the threshold cycle (Ct) for each gene and normal-
ized using the average of four housekeeping genes on the
same array (HPRT1, RPL13A, GAPD, ACTB). Ct values for
housekeeping genes and a dilution series of ACTB were mon-
itored for consistency between arrays. Change (∆Ct) between
MUC1 siRNA and control siRNA was found by:
∆Ct = Ct(MUC1 siRNA) - Ct(control siRNA)
and fold change by:
Fold change = 2(-∆Ct)
Values are given as fold change; only genes showing two-fold
or greater change were considered. Both luciferase and
scrambled siRNA controls were used in BT-20; only genes
showing consistent alteration with both controls were
included in the results reported here. The scrambled siRNA
could be not used in MDA-MB-468 as these cells decrease
MUC1 expression in response to this construct.
Results
siRNA transfection decreases MUC1 expression in 
breast cancer cell lines
Two human breast cancer cell lines, MDA-MB-468 and BT-20,
were transiently transfected with a pool of four siRNA oligonu-
cleotides directed against the MUC1 mRNA (468.siMUC1
and BT.siMUC1), or a control oligonucleotide directed against
luciferase (468.siLuc and BT.siLuc). Both cell lines express
high levels of MUC1, making them promising targets for this
analysis. Western blots (Figure 1a) show successful knock-
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fragments of MUC1; luciferase siRNA does not substantially
change the level of MUC1 compared to parental cells.
468.siMUC1 show a substantial decrease in the amount of
MUC1-CT, while BT.siMUC1 show slightly less knockdown of
MUC1-CT. Both MDA-MB-468 and BT-20 display a less dra-
matic decrease of MUC1 extracellular domain compared to
MUC1-CT (Figure 1a); this likely represents protein synthe-
sized prior to transfection, and may reflect differences in the
turnover rates of the two subunits.
Analysis of the MUC1 extracellular domain by flow cytometry
confirms that both cell lines substantially decrease MUC1
expression after siRNA (Figure 1b). By flow cytometry,
468.siMUC1 averaged 75% knockdown of MUC1 compared
to 468.siLuc; and BT.siMUC1 averaged 50% knockdown rel-
ative to BT.siLuc. These effects could be titrated with the con-
centration of siRNA, were seen as early as 24 hours post-
transfection (data not shown) and lasted to at least 96 h post-
transfection (Figure 1b). All experiments were conducted
within 48 to 96 hours after siRNA transfection. Similar results
were obtained using two independent oligonucleotides
designed in our lab (data not shown), designated '882' and
'956' for the initial codon recognized by each.
Transcriptional changes are seen after MUC1 siRNA
Recent work indicates that MUC1 may affect transcription
both directly via interaction with transcription factors and indi-
rectly (for example, through modulating signaling). To study
the effects of MUC1 knockdown in breast cancer cell lines,
real-time PCR arrays were used to analyze transcription of 84
genes implicated in cancer. Only genes with greater than two-
fold change were considered. Three genes (MAP2K1, VEGF,
PDGFA) were altered two-fold or more after MUC1 siRNA in
both MDA-MB-468 and BT-20 cells (Figure 2); two genes
(ITGAV, MMP2) changed only in 468.siMUC1; and five genes
(TIMP3, RAF1, JUN, TNF, CDC25A) only in BT.siMUC1. This
list represents all genes affected greater than two-fold after
MUC1 siRNA, rather than a select group. Three genes whose
transcription was changed by less than two-fold are shown,
two of which (PDGFB and ITGB1) are listed because they
relate closely to genes altered by two-fold (PDGFA  and
ITGAV). The third, MYC, is included because western blots
confirmed a substantial change at the protein level (Figure 3a)
that may reflect both transcriptional and post-transcriptional
regulation.
Figure 1
Small interfering RNA (siRNA) decreases MUC1 levels in breast cancer  cells Small interfering RNA (siRNA) decreases MUC1 levels in breast cancer 
cells. (a) Western blots (IB) of the MUC1 cytoplasmic tail (MUC1-CT) 
and extracellular domain (MUC1-EX) in untreated (parental), or luci-
ferase siRNA treated (siLuc) or MUC1 siRNA (siMUC1) treated MDA-
MB-468 and BT-20 cells. Lysates were analyzed 48 hours post-trans-
fection; tubulin is shown as a loading control. (b) Flow cytometry analy-
sis of the MUC1 extracellular domain in unpermeabilized, siRNA-
treated MDA-MB-468 and BT-20 lines. Cells were analyzed at 24 hour 
intervals beginning 48 hours post-transfection. The black line repre-
sents isotype control, the green luciferase siRNA (siLuc), and the red 
MUC1 siRNA (siMUC1).
Figure 2
Transcription of genes involved in cancer is altered in response to  MUC1 small interfering RNA (siRNA) Transcription of genes involved in cancer is altered in response to 
MUC1 small interfering RNA (siRNA). Genes whose transcription was 
altered by at least two-fold in MUC1 siRNA-treated cells compared to 
control siRNA are shown. Green bars represent genes whose tran-
scription was up-regulated; red bars are genes whose transcription 
was down-regulated after MUC1 siRNA. The average fold change is 
shown in parentheses after the gene name; for genes altered in both 
MDA-MB-468 and BT-20, these values reflect the average from both 
cell lines.Available online http://breast-cancer-research.com/content/8/4/R37
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Interestingly, transcription of MAP2K1 was decreased in both
cell lines after MUC1 siRNA. This gene encodes MEK1, one
of the primary regulators of the ERK1/2 MAPK pathway [33],
a network that has been linked several times to MUC1 [12,34-
36]. We examined MEK1 and MEK2 levels by western blot to
confirm decreased protein in MUC1 siRNA-treated cells (Fig-
ure 3a), and found that not only were total MEK1/2 levels
lower in 468.siMUC1 and BT.siMUC1 compared to controls
(0.48 and 0.68 relative to siLuc, respectively), but so were the
basal amounts of active (phosphorylated) MEK1/2 (pMEK1/2;
0.12 and 0.42 relative to siLuc, respectively). Both
468.siMUC1 and BT.siMUC1 also showed reduced activation
of ERK1/2 (dpERK1/2; 0.21 and 0.27 relative to siLuc,
respectively), as would be expected with diminished signaling
through MEK1/2; total ERK1/2 levels remain unchanged.
As both lines have high levels of EGFR and thus activate the
MEK-ERK cascade intensely when stimulated with EGF [37],
siRNA-transfected cells were treated with EGF. Notably,
MUC1 siRNA impairs this important oncogenic pathway in
MDA-MB-468 cells, as 468.siMUC1 display less pMEK1/2 in
response to EGF than do 468.siLuc (Figure 3b). Interestingly,
EGF treatment of BT-20 cells results in slightly higher pMEK1/
2 levels in BT.siMUC1 compared to BT.siLuc. Though this
result seems paradoxical in light of decreased MAP2K1 tran-
scription in BT.siMUC1, it likely results from differential func-
tions of Raf isoforms in combination with the increased RAF1
transcription (Figure 2) and protein level (Figure 3a) in these
cells. Specifically, B-Raf is thought to be the main activator of
MEK under normal conditions; Raf-1 activates MEK in
response to stimulus [38]. Thus, it appears that basal pMEK1/
2 levels are not greatly affected by Raf-1 overexpression in
BT.siMUC1 cells, likely because MEK is regulated primarily by
B-Raf under normal growth conditions. In contrast, when the
cells are stimulated (EGF), increased Raf-1 levels in
BT.siMUC1 leads to heightened pMEK1/2 (Figure 3b).
MUC1 siRNA increases apoptosis in MDA-MB-468 but 
not BT-20
We next examined whether MUC1 knockdown and its associ-
ated transcriptional alterations would affect overall cellular
events. As several of the genes shown in Figure 2 are impor-
tant in regulating proliferation and survival, and because of the
recently described role of MUC1 in modulating apoptosis in
response to cellular stresses [20,21,24], we first analyzed
whether MUC1 siRNA would alter apoptosis in these lines.
Although there was no change in basal apoptosis in either line
(Figure 4a), we observed that the cell lines responded differ-
ently when trypsinized for re-plating 24 hours after transfection
Figure 3
Western blot analysis confirms changes in protein levels after MUC1  small interfering RNA (siRNA) Western blot analysis confirms changes in protein levels after MUC1 
small interfering RNA (siRNA). (a) Whole cell lysates were analyzed for 
the following proteins: MUC1 extracellular subunit (MUC1-EX), c-Myc, 
total and active MAPK and ERK kinase (MEK)1/2 (MEK1/2, pMEK1/2), 
total and active extracellular signal regulated kinase (ERK)1/2 (ERK1/2, 
dpERK1/2), total and active AKT (AKT, pAKT), and tubulin as a loading 
control. Densitometry is shown for each blot, based on three independ-
ent measurements per band, normalized to tubulin; results are shown 
relative to luciferase siRNA (siLuc) for each cell line. Optimal exposures 
for comparing luciferase siRNA and MUC1 siRNA-treated cells from 
the same parental line are shown. (b) Lysates from epidermal growth 
factor (EGF)-stimulated MDA-MB-468 cells were blotted for MEK1/2, 
pMEK1/2, MUC1-EX, and actin (for loading).
Figure 4
MUC1 small interfering RNA (siRNA) affects cell death in response to  stress in MDA-MB-468, but not BT-20 cells MUC1 small interfering RNA (siRNA) affects cell death in response to 
stress in MDA-MB-468, but not BT-20 cells. (a) Basal apoptosis is 
shown as the combined total of early (propidium iodide (PI)-/annexin 
V+) and late (PI+/annexin V+) apoptotic populations. Results reflect the 
averages of three independent experiments. (b) Apoptosis after 
trypsinization 24 hours post-transfection. Numbers in the quadrants 
reflect the percentage of cells in each. Representative flow cytometry 
results are shown for MDA-MB-468 and BT-20 cells transfected with 
siRNA. (c) Total cell death (sum of non-apoptotic cell death (PI+/
annexin V-), and early and late apoptosis) is shown for MDA-MB-468 
cells in response to a panel of cellular stresses (G418, trypsin, perox-
ide, celecoxib) and controls (control, DMSO). Representative results 
from three independent experiments are shown. (d) Western blots (IB) 
for total and active AKT (AKT, pAKT) and tubulin loading control, per-
formed on whole cell lysates from siRNA transfected cells. The same 
exposure is shown for both cell lines to show the relative levels of pro-
tein between lines, rather than optimal exposure times for comparison 
within a single cell line (shown in Figure 3a).Breast Cancer Research    Vol 8 No 4    Hattrup and Gendler 
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(Figure 4b). Interestingly, 468.siMUC1 cells show greater
apoptosis after trypsinization than do 468.siLuc (49.8% ver-
sus 34.0%, respectively), while BT-20 cells from both siRNA
treatments display similar levels of apoptosis (around 22%).
To examine whether this phenomenon is specific to trypsin
treatment or part of a general stress response involving
MUC1, we subjected cells to a panel of stresses and meas-
ured cell death. In agreement with the patterns seen with
trypsinization, BT.siLuc and BT.siMUC1 respond similarly to
all treatments (data not shown), while 468.siMUC1 die more
readily than 468.siLuc in response to trypsin, G418, hydrogen
peroxide, or celecoxib, a chemotherapeutic that targets the
cyclooxygenase-2 (COX-2) pathway (Figure 4c); these data
were confirmed with two independent siRNA constructs (data
not shown).
Like the MAPK pathway, AKT signaling has been linked to
MUC1 in cancer. Although transcription of AKT  was not
altered in MUC1 siRNA-treated cells, the results of our apop-
tosis studies prompted us to investigate levels of AKT further.
As expected, the total AKT protein level is not greatly changed
after MUC1 siRNA in either cell line, though the active form
(pAKT) is increased in both 468.siMUC1 and BT.siMUC1
compared to controls (Figure 3a). This result disagrees with
MUC1 activation of the AKT pathway in rat 3Y1 cells [18], and
may reflect regulation more appropriate to breast cancer cells;
this is supported by activation of AKT in response to MUC1
siRNA in other lines [21]. In addition, there is a striking differ-
ence in the relative amounts of AKT and pAKT in the two cell
lines (Figure 4d). When lysates from both lines are exposed to
film for the same length of time (overexposure masks the dif-
ferences between BT.siLuc and BT.siMUC1 that are apparent
in Figure 3a), it is clear that pAKT levels are much higher in BT-
20 than in MDA-MB-468, despite lower total AKT expression.
This difference in AKT activation between MDA-MB-468 and
BT-20 likely contributes to the disparity in their sensitivity to
the increased apoptosis expected with loss of MUC1.
MUC1 siRNA alters proliferation and invasion
As MUC1 is involved in apoptosis, we next analyzed its effects
on proliferation. BrdU and [3H]thymidine incorporation were
used to analyze proliferation after MUC1 siRNA. 468.siMUC1
cells show a significant decrease in [3H]thymidine incorpora-
tion compared to 468.siLuc, while intriguingly, BT.siMUC1
cells show a significant increase in proliferation (Figure 5a).
Growth curves mirror these results, as do experiments with the
two independent MUC1 siRNA oligonucleotides (data not
shown). Note that these assays require trypsinizing cells 24
hours post-transfection; therefore, the results in the MDA-MB-
468 line could stem from the changes in apoptosis described
in the previous section, rather than a true effect on prolifera-
tion. To control for this, we incubated non-trypsinized, siRNA-
transfected cells at similar confluence with BrdU to measure
incorporation. The 'clumped' profile of cells (contrast to Figure
Figure 5
Proliferation is altered by MUC1 small interfering RNA (siRNA) in both  cell lines Proliferation is altered by MUC1 small interfering RNA (siRNA) in both 
cell lines. (a) [3H]Thymidine incorporation is shown by the level of radi-
oactivity (cpm) emitted from cells after 24 hours incubation with radio-
nucleotide. Results reflect the average of three independent 
experiments. *p < 0.006 compared to luciferase siRNA (siLuc) treated 
cells of the same line (that is, 468.siLuc or BT.siLuc). (b) Flow cytomet-
ric analysis of bromodeoxyuridine (BrdU) incorporation. siRNA-trans-
fected cells were incubated with BrdU for 1.5 hours, and stained with a 
Phycoerythrin PE-conjugated antibody against BrdU. A representative 
experiment is shown. (c) Invasion of MDA-MB-468 cells in transwells 
plated with a panel of extracellular matrix proteins or no matrix (control). 
Representative results are shown as percent invasion, calculated as: 
number of invaded cells/total number of cells × 100.Available online http://breast-cancer-research.com/content/8/4/R37
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4b) is likely a result of the acid denaturation (recommended by
the antibody manufacturer), as it occurs uniformly in these
experiments. BrdU incorporation (Figure 5b) confirms that the
[3H]thymidine results are not solely due to alterations in apop-
tosis, as 468.siMUC1 cells incorporate less BrdU than
468.siLuc; once again, BT.siMUC1 cells show increased pro-
liferation over BT.siLuc.
Given the role of MUC1 in adhesion, we examined whether
MUC1 siRNA affects cellular invasion. In transwell assays, BT-
20 cells invaded poorly, regardless of the siRNA used (data
not shown). However, MDA-MB-468 cells invade more readily,
and were analyzed on a panel of three different extracellular
matrix proteins. Interestingly, 468.siMUC1 cells display some-
what decreased invasion on collagen IV, laminin, and fibronec-
tin matrices, and on a no-matrix control (Figure 5c), which is in
agreement with the trend towards decreased metastasis
observed in Muc1-/- × MMTV-PyV MT mice [8].
Transfection of MUC1 rescues the 468.siMUC1 
phenotype
To determine if the above effects are specific to MUC1, we
created stable transfectants of the MDA-MB-468 line using
empty vector (468.Neo) or a full-length MUC1 construct
(468.MUC1∆8) that is resistant to one of the independent
MUC1-directed oligonucleotides ('882'). These cells were
maintained in G418-containing medium to retain transgene
selection. As expected, 468.MUC1∆8 cells show higher levels
of both the MUC1 extracellular domain and the MUC1-CT
than do 468.Neo (Figure 6a). Note that 468.Neo have MUC1
expression comparable to parental MDA-MB-468; the expo-
sures in Figure 6a are lighter than those in Figure 1a, in order
to clearly show the relative levels of MUC1 in the stable trans-
fectants. After MUC1 siRNA, 468.MUC1∆8 lose some MUC1
(likely endogenous protein, which is not siRNA-resistant) but
retain high-level expression, while 468.Neo show a decrease
in MUC1 levels similar to parental 468.siMUC1 cells (Figures
6a,b). The difference in the amount of MUC1 knockdown
between 468.Neo and 468.MUC1∆8 is highlighted by the
purple shading in Figure 6b.
BrdU incorporation (Figure 6c) indicates that 468.Neo show
decreased nucleotide incorporation after MUC1 siRNA com-
pared to control (3.3% versus 25.0%, respectively); this is not
seen in 468.MUC1∆8 cells, which show similar levels of BrdU
incorporation regardless of the siRNA used (21.5% for luci-
ferase, 23.9% for MUC1). 468.Neo cells display a more dra-
matic decrease in BrdU incorporation after MUC1 siRNA than
what is seen in parental 468.siMUC1 cells, which may reflect
the additional stress of being maintained in G418-containing
medium. Similarly, analysis of apoptosis in trypsinized cells
indicates that the increased apoptosis seen in parental
468.siMUC1 cells is also present in the 468.Neo line after
MUC1 siRNA (Figure 6d; 43.6% in control versus 59.6% in
MUC1 siRNA). However, in 468.MUC1∆8 cells, the level of
apoptosis after luciferase siRNA (34.1%) is lower than that in
468.Neo cells; MUC1 siRNA increases the amount of apopto-
sis slightly (42.8%), restoring it to a level similar to that seen in
luciferase siRNA-treated 468.Neo cells. Together, these stud-
ies suggest that the above-described results are specific to
MUC1, as stable transfection of an siRNA-resistant MUC1
rescues the phenotype seen in 468.siMUC1 cells.
Discussion
This report describes both the transcriptional alterations seen
after transfection with MUC1 siRNA in human breast cancer
cells and the effects on events such as apoptosis and prolifer-
ation. The two cell lines used (MDA-MB-468 and BT-20) were
chosen for high expression of MUC1 and a substantial (50%
to 75%), consistent decrease in MUC1 expression after
Figure 6
The MUC1 interfering RNA (siRNA) phenotype is rescued by stable  transfection with MUC1 The MUC1 interfering RNA (siRNA) phenotype is rescued by stable 
transfection with MUC1. (a) MDA-MB-468 cells transfected with a full-
length, siRNA-resistant MUC1 construct (468.MUC1∆8) or empty vec-
tor (468.Neo); lysates were blotted for MUC1 extracellular (MUC1-EX) 
and cytoplasmic (MUC1-CT) domains, with actin as a loading control. 
The left panel shows untransfected cells; the right shows siRNA treat-
ment of the stable transfectants and parental cells. (b) siRNA-trans-
fected 468.Neo and 468.MUC1∆8 cells were stained for expression of 
MUC1-EX 48 hours post-transfection and analyzed by flow cytometry. 
The black line represents isotype control, the green luciferase (Luc) 
siRNA, and the red MUC1 siRNA. Arrows point out the shaded regions 
that reflect the level of knockdown in each cell line. (c) Flow cytometric 
analysis of bromodeoxyuridine (BrdU) incorporation after 1.5 hours 
incubation with siRNA transfected cells. The number shown in each 
upper left quadrant reflects the percentage of BrdU-positive cells. A 
representative experiment is shown. (d) Total apoptosis is shown as 
the sum of early (propidium iodide (PI)-/annexin V+) and late (PI+/
annexin V+) apoptotic populations for 468.Neo and 468.MUC1∆8 cells 
trypsinized 24 hours post-transfection. A representative example is 
shown.Breast Cancer Research    Vol 8 No 4    Hattrup and Gendler 
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siRNA. Both lines have epithelial morphology, form tumors
slowly in nude mice [37], have mutant p53 [39,40], express
EGFR [37], and lack estrogen receptor α [41]. One striking
difference between these lines, however, is their response to
MUC1 siRNA. MDA-MB-468 cells behave as expected for
loss of an oncogene: MUC1 siRNA correlates with increased
apoptosis in response to stress, decreased proliferation, and
reduced invasion. In contrast, BT.siMUC1 cells proliferate
more rapidly than BT.siLuc cells with little effect on apoptosis.
Much of the phenotype of these cells can be understood in
light of protein levels and transcriptional activity after MUC1
siRNA. As mentioned, both MDA-MB-468 and BT-20 display
increased pAKT after MUC1 siRNA, but the ratio of active to
total AKT is considerably higher in the BT-20 line, which may
help these cells resist the increased apoptosis expected with
loss of MUC1. Myc levels are also higher in both cell lines after
MUC1 siRNA, although the ability of Myc to promote prolifer-
ation and apoptosis in different cellular contexts [42] compli-
cates the interpretation of this finding.
Both cell lines show reduced transcription of VEGF, PDGFA,
PDGFB, and MAP2K1 (MEK1) after MUC1 siRNA. The genes
encoding vascular endothelial growth factor (VEGF) and the A
and B chains of platelet-derived growth factor (PDGF-A and
PDGF-B) are interesting as these proteins have been heavily
implicated in angiogenesis, suggesting a novel function for
MUC1 in regulating this process. Vascular endothelial growth
factor expression in cancer is linked to tumor growth and
metastasis [43,44]; platelet-derived growth factor is also ang-
iogenic, but has an additional role in stimulating desmoplasia
[45]. Reduced transcription of these genes after MUC1 siRNA
suggests that MUC1 may foster angiogenesis and stromal
proliferation, although this must be confirmed in a more appro-
priate model system.
Decreased MAP2K1 (MEK1) transcription after MUC1 siRNA
provides a novel mechanism by which MUC1 can affect the
ERK1/2 MAPK pathway. MUC1 has often been linked to the
Ras-Raf-MEK-ERK cascade [12,34-36,46], and at least two
mechanisms by which MUC1 can alter MAPK signaling have
been described: MUC1 interaction with and phosphorylation
by the EGFR family [12,13], and MUC1 binding to the Grb2/
Sos complex that activates Ras [46]. Reduction of MEK1 lev-
els after MUC1 siRNA agrees with the role of MUC1 in
strengthening MAPK signaling, and indicates that MUC1 can
regulate both the transcription and activity of members of this
pathway.
Two additional MAPK pathway members are altered specifi-
cally in BT.siMUC1, with no corresponding change in
468.siMUC1 cells. These genes are RAF1 and JUN which are
increased and decreased, respectively, after MUC1 siRNA.
Raf-1 and c-Jun both function outside of the ERK1/2 MAPK
pathway, which may explain the seeming paradox of increased
RAF1 transcription with simultaneous decreases in MAP2K1
and JUN. Specifically, Raf-1 can inhibit ASK1 (apoptosis sig-
nal-regulated kinase 1) upstream of p38 and JNK (Jun N-termi-
nal kinase) [38]. ASK1 phosphorylates JNK in response to
stress, resulting in activation of c-Jun and stimulation of apop-
tosis [47], indicating that the coordinate up-regulation of
RAF1 and down-regulation of JUN may provide a potent anti-
apoptotic effect in BT.siMUC1.
Regulation of life and death is also a hallmark of the CDC25A
and TNF gene products. CDC25A is a phosphatase that stim-
ulates cell cycle progression [48], thus the effects of its
decrease in BT.siMUC1 are unclear in light of the increased
proliferation of these cells. However, the CDC25 proteins (A,
B, and C) were recently shown to have greater functional over-
lap than was previously thought [49], suggesting that the other
two isoforms may compensate for reduced CDC25A levels.
TNF  encodes tumor necrosis factor (TNF)α, known for its
potent, cell type-specific control of life and death. In tumor
cells, TNFα expression can promote proliferation and inhibit
apoptosis [50], suggesting that increased TNF transcription in
BT.siMUC1 could contribute to the increased proliferation
seen in these cells.
Interestingly, the increase in TNF  is accompanied by
decreased transcription of TIMP3, encoding tissue inhibitor of
metalloproteinases (TIMP)3. The TIMP family disrupts the
function of matrix metalloproteinases (MMPs), generally result-
ing in decreased invasion [51]. TIMP3 is unique in that it can
also inhibit TNFα converting enzyme (TACE), which activates
TNFα by cleaving it from the cell surface [50]. Reduced
expression of TIMP3 would, therefore, foster signaling through
TNFα by releasing inhibition of TNFα converting enzyme. In
agreement with this, TIMP3 can promote apoptosis [52]; thus,
its down-regulation in BT.siMUC1 provides another mecha-
nism by which these cells are able to resist the increased
apoptosis expected with loss of MUC1.
A n o t h e r  T I M P  t a r g e t  r e s p o n d s  t o  M U C 1  s i R N A ,  a s
468.siMUC1 cells show significantly increased expression of
MMP2 (encoding MMP-2/gelatinase A), the product of which
degrades type IV collagen [52]. In breast cancer, the ratio of
active to latent MMP-2 increases with tumor progression;
MMP-2 may facilitate both angiogenesis and metastasis [52].
Its increase after loss of MUC1 is, therefore, unexpected, but
at least two factors may clarify this result. First, though MMP-
2 levels are increased in mouse mammary tumors, its expres-
sion is confined to the stroma [53], suggesting that increased
MMP2  transcription after loss of the epithelium-specific
MUC1 might reflect a shift towards a more mesenchymal phe-
notype. Second, MMP-2 levels are increased by overexpres-
sion of erbB2 [52]; previous studies have shown that erbB2
and Muc1 expression are mutually exclusive in mammary
tumors [27], implying that MMP2 might be part of a transcrip-
tional profile linked to low MUC1 levels.Available online http://breast-cancer-research.com/content/8/4/R37
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It is intriguing that, despite increased MMP2  transcription,
invasion is decreased in 468.siMUC1 cells, even on collagen
IV. This may reflect insufficient activation of MMP-2, as the pre-
cursor protein must be cleaved for enzymatic function [52].
Alternatively, the slowed invasion of these cells may relate to
impaired adhesion resulting from decreased transcription of
ITGAV and ITGB1 (αv and β1 integrins, respectively). Integrin
signaling is tied to life-or-death decisions in epithelial cells,
and integrin expression is vital for processes from wound heal-
ing to metastasis [54]. Integrin αvβ3 is implicated in facilitating
metastasis of breast cancer cells to bone [55]; decreased
transcription of ITGAV after MUC1 siRNA may, therefore, sug-
gest that MUC1 is involved in this lethal process as well.
The MUC1 oncogene has been linked to apoptosis
[18,20,26], proliferation [17], and transcription [21,23-25] in
cancer. However, the two cell lines chosen for our study dis-
play very different responses to MUC1 siRNA, indicating that
regulation of MUC1 in breast cancer is likely quite complex
and cautioning against over-generalization of results from indi-
vidual cell lines. Previous reports suggest that, though most
studies outline a clearly oncogenic role for MUC1 in breast
cancer, the exact details may vary depending on factors such
as cell type and signaling context. For example, MUC1 stimu-
lates Fas-mediated apoptosis in CHO cells [26], quite unlike
the inhibition of apoptosis seen in other cell lines. Similarly,
though MUC1 drives mammary oncogenesis in its own right
[9] and facilitates tumorigenesis driven by other oncogenes
[7,8], Muc1 is selectively down-regulated in c-neu-induced
mouse mammary tumors [27], indicating that the context of
oncogenic signaling is vital to understanding the function of
MUC1.
Thus, it is important to consider the relative levels of knock-
down of MUC1 in the two cell lines: BT-20 cells reduce MUC1
expression after siRNA less strongly than do MDA-MB-468
(50% versus 75% knockdown, respectively). As MUC1 serves
as a scaffold [11], overexpression of MUC1 relative to its asso-
ciated signaling proteins might create a dilution effect,
sequestering signal transducers away from each other; this
would be relieved by MUC1 siRNA. Thus, enough MUC1 may
be retained in BT.siMUC1 cells for its oncogenic effects, while
signaling complex formation would be enhanced by lowering
the amount of MUC1 relative to other signaling proteins.
Conclusion
The contrast between the MDA-MB-468 and BT-20 lines in
response to MUC1 siRNA serves as a reminder that simplified
models such as cell lines fail to encompass the complexity of
intact biological systems. This report describes transcriptional
alterations seen after MUC1 knockdown: decreased transcrip-
tion of MAP2K1, VEGF, PDGFA, ITGAV, TIMP3, CDC25A,
and JUN, and increased transcription of MMP2, TNF, and
RAF1. The alterations in MAP2K1, RAF1, and JUN represent
a novel means by which MUC1 can affect ERK1/2 signaling:
transcriptional regulation of MAPK pathway members. Onco-
genic events are also altered in both cell lines after MUC1
siRNA. These results strengthen the growing ties linking
MUC1 and transcriptional regulation, and suggest that the role
of MUC1 in breast cancer may be more complex than a direct
correlation between MUC1 level and oncogenic function.
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